Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT05011097 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Start date: July 8, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this Phase I study is to access the safety and tolerability of Y150 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.

NCT ID: NCT05011045 Recruiting - Lymphoma Clinical Trials

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Start date: January 9, 2020
Phase:
Study type: Observational

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

NCT ID: NCT05008536 Recruiting - Clinical trials for Multiple Myeloma, Refractory

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Start date: October 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to infuse BCMA CAR-NK cells(Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells) to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

NCT ID: NCT05007652 Completed - Clinical trials for Multiple Myeloma and Malignant Lymphoma

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.

NCT ID: NCT05007418 Recruiting - Multiple Myeloma Clinical Trials

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

NCT ID: NCT05006469 Recruiting - Multiple Myeloma Clinical Trials

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

Observe the best dose, efficacy and adverse reactions of BAd in the treatment of relapsed and refractory multiple myeloma.

NCT ID: NCT05005299 Recruiting - Clinical trials for Myelodysplastic Syndromes

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

VICTORY
Start date: June 8, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned for allogeneic stem cell transplantation (alloSCT). The primary study objective is to determine the safety and maximum tolerated dose of venetoclax when used in combination with fludarabine and cyclophosphamide conditioning. Secondary objectives were to evaluate the transplant outcomes and donor/recipient engraftment of this regimen.

NCT ID: NCT05002816 Recruiting - Multiple Myeloma Clinical Trials

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Start date: February 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

NCT ID: NCT05001087 Recruiting - Multiple Myeloma Clinical Trials

A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

MY MYELOMA
Start date: March 16, 2021
Phase:
Study type: Observational [Patient Registry]

The aim of this observational study is the creation of a national multiple myeloma registry to monitor the current routine clinical practice in Italy and describe the standard of care adopted for the diagnosis and treatment of patients with multiple myeloma in the different Italian hematology centers.

NCT ID: NCT05000450 Active, not recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Start date: June 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.